Skip to main content
. 2014 Jun 24;9(6):e99484. doi: 10.1371/journal.pone.0099484

Figure 1. Effects of mCAR ligands alone or in combination with Paclitaxel in E9 mouse lung cancer cells.

Figure 1

(A) Cell viability after 48 hours of different concentrations of the mCAR agonist TCPOBOP or the mCAR inverse-agonist androstenol. TCPOBOP has no effect on cell viability even at the highest concentration. On the other hand, androstenol increases the number of E9 cancer cells dose-dependently (* p<0.05 – Two way ANOVA followed by Tukey's multiple comparison test for treatment effect). (B) Effects of mCAR ligands on the anti-tumor efficacy of paclitaxel (IC50). TCPOBOP increases the anti-tumor efficacy of the of paclitaxel by significant decrease cell viability at 1–10 µM compared to only paclitaxel-treated cells (p<0.05 – Two way ANOVA followed by Tukey's multiple comparison test for treatment effect). The androstenol partially abolishes the anti-tumor efficacy of paclitaxel (p<0.05 – Two way ANOVA followed by Tukey's multiple comparison test for treatment effect). (C) Gene expression of mCAR in cells treated with ligands alone, paclitaxel alone, or in combination. Ligands did not alter mCAR gene expression. Note that all paclitaxel treated-groups presented increased mCAR gene expression compared to control group (* p<0.05 – One way ANOVA).